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Abstract.  We have recently shown that urokinase-type 
plasminogen activator (u-PA) and plasminogen activa- 
tor inhibitor type 1 are both found extracellularly be- 
neath cultured human skin fibroblasts and HT-1080 
sarcoma cells, but in distinct localizations. Here, the 
ultrastructural distribution of u-PA was studied using 
immunoferritin electron microscopy. In HT-1080  cells, 
u-PA on the extracellular aspect of the plasma mem- 
brane was detected at sites of direct contact of the cell 
with the growth substratum beneath all parts of the ven- 
tral cell surface. The ferritin-labeled adhesion plaques, 
which were enriched in submembraneous microfila- 
ments, were frequently seen at the leading lamellae of 
the cells as well as in lamellipodia and microspikes. 
Besides the cell-substratum adhesion plaques, ferritin 
label was detected at cell-cell contact sites. 
Double-label immunofluorescence showed a  striking 
colocalization of u-PA and vinculin in both HT-1080 
cells and WI-38 lung fibroblasts, which is consistent 
with u-PA being a  focal contact component. The u-PA- 
containing focal contacts of WI-38 cells had no direct 
codistribution with fibronectin fibrils. In WI-38 cells 
made stationary by cultivation in a  medium containing 
0.5 % FCS, vinculin plaques became highly elongated 
and more centrally located, whereas u-PA immuno- 
label disappeared from such focal adhesions. These 
findings show that plasma membrane-associated u-PA 
is an intrinsic component of focal contacts, where, we 
propose,  it enables directional proteolysis for cell 
migration and invasion. 
rIESIVE interactions of cells with the extracellular ma- 
trix and their reversal are critical events for morpho- 
genetic movements during embryonic development 
and for cancer cell invasion during metastasis (30, 49). The 
molecular structures at the sites where cultured cells contact 
each other and the growth substratum are thus of great in- 
terest. Focal contacts, the sites of closest cell-substratum ap- 
position, can be visualized either by electron microscopy (1) 
or by interference reflection microscopy (23). Focal contacts 
are localized at the termini of actin-containing microfilament 
bundles, and contain vinculin (7, 19) and talin (6) on the cyto- 
plasmic side, but apparently do not have fibronectin on the 
extracellular side (9). The so-called close contacts exhibit a 
greater substrate separation distance, do not contain vincu- 
lin,  and probably represent a  more labile type of contact 
(23).  A  third kind of substrate  adhesion  site termed the 
fibronexus (42)  or extracellular matrix contact site (9)  is 
characteristic of well-spread and stationary fibroblasts.  It 
features a codistribution of fibronectin, its plasma membrane 
receptor, actin, vinculin, and alpha-actinin throughout the 
entire contact site and is located at central regions of the cell 
rather than at its margins (11, 15). Fibronexuses show very 
close transmembrane associations of actin microfilaments 
and fibronectin fibrils (42,  43). 
Urokinase-type plasminogen activator (u-PA) ~ is one of 
the two well-characterized types of serine proteinases that 
convert the extracellular proenzyme plasminogen into the 
active proteinase plasmin (for reviews see references 4, 16). 
It is synthesized  as an inactive single-chain proactivator (pro- 
u-PA) by many types of cells (17, 32, 44, 45, 52), and most 
of the enzyme is in the proactivator form also in vivo (28). 
Pro-u-PA is converted to the active two-chain form in a reac- 
tion that may be catalyzed by plasmin. Specific u-PA recep- 
tors were recently detected in human monocytes and mono- 
cyte-like cells (46, 50), and also in several other cell types 
(for reviews see references 3, 4). These receptors bind u-PA 
at its growth factor domain (2),  with a  high affinity, Kd 
10  -I~ M. According to experiments with human A-431 epi- 
dermoid cells, pro-u-PA is first secreted and then bound to 
its specific plasma membrane receptors (47). 
PAs are thought to play an important role in controlling ex- 
traceUular proteolysis (37).  Plasminogen and PAs have af- 
finity for extracellular matrix components laminin (40) and 
fibronectin (39), and a Mr 66,000 matrix-associated protein 
1. Abbreviations  used in this paper:  anti-TNP-lgG,  monoclonal mouse IgG 
antibody against trinitrophenyl group; pro-u-PA, inactive single-chain pro- 
activator;  TRITC,  tetramethylrhodamine isothiocyanate,  u-PA, urokinase- 
type plasminogen  activator. 
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Furthermore, plasmin is able to activate latent collagenases, 
proteinases involved in the degradation of interstitial matrix 
and basement membranes (33, 34, 38). Extracellular matrix 
degradation by Rous sarcoma virus-transformed fibroblasts 
probably consists of both plasminogen-dependent and -inde- 
pendent pathways (18), and a direct catalytic role for PA in 
the process has been suggested (48).  External proteolysis 
taking place at cellular contact sites would be advantageous 
to cells actively migrating or invading surrounding tissues. 
Focal proteolysis of fibronectin substrate occurs in Rous sar- 
coma virus-transformed fibroblasts (10, 12), involving a Mr 
150,000 metalloendoproteinase and a Mr 120,000 serine pro- 
teinase (8). 
We have previously shown that u-PA is extracellularly lo- 
cated beneath cultured cells,  and that the distributions of 
u-PA and plasminogen activator inhibitor type 1 under the 
cells are mostly distinct (35). In this report, we have iden- 
tiffed the u-PA-containing structures. To do this, immunofer- 
ritin bridge electron microscopy was chosen as a method to 
examine the ultrastrnctural distribution of extracellular u-PA 
in HT-1080 sarcoma cells. In addition, double-label immu- 
nofluorescence  staining of u-PA and vinculin was performed. 
Materials and Methods 
Cell Cultures 
The human fibrosarcoma cell line HT-1080 and WI-38 human embryonic 
lung fibroblasts were obtained from American Type Culture Collection, 
Rockville, MD (ATCC, CCL 121, and CCL 75, respectively). The cells were 
grown in plastic dishes (53 cm  2 or 19.7 cm  2) in Eagle's minimal essential 
medium (MEM) supplemented with 10% FCS (Gibco, Paisley,  UK), 100 
IU/ml penicillin and 50 Ilg/ml streptomycin. Cells were plated on glass cov- 
erslips and fixed and processed after 24 h of subculture at subconfluent den- 
sity or were processed as specified in the text. 
lmmunofluorescence 
Polyclonal purified rabbit IgG against u-PA was prepared as described else- 
where (29) and detected both active u-PA and its proenzyme (31). Monoclo- 
nal anti-vinculin mouse IgGj was from Bio-Yeda (Kiryat Weizmann, Re- 
hovot, Israel). Monoclonal mouse IgGt  fpg-9 to fibronectin was described 
previously (35).  Monoclonal mouse IgG antibody against the trinitrophenyl 
group (anti-TNP-IgG)  was from the hybridoma clone designated Hy 2.15 
(41).  FITC-conjugated sheep anti-mouse IgG was from Cappell Laborato- 
ries, Cochranville, PA, and tetramethylrhodamine isothiocyanate (TRITC)- 
conjugated goat anti-rabbit IgG from Nordic Immunological Laboratories, 
Tilburg, The Netherlands. 
For immunofluorescent staining, rinsed coverslip cultures of cells were 
fixed with -20~  methanol. Cells were treated with the primary antibodies 
diluted in PBS at a concentration of 50 pg/ml (anti-u-PA-IgG)  or hybridoma 
supernatants diluted 1:30 (monoclonal antivinculin or fpg-9 antifibronectin) 
for 30 min. This was followed by a short rinse in PBS and treatment with 
the fluorochrome (FITC/TRITC)-conjugated secondary antibodies for 30 
rain. For double immunofluorescent studies of u-PA and vinculin/fibronec- 
tin the cells were treated in the following sequence: rabbit anti-u-PA IgG, 
goat anti-rabbit IgG-TRITC,  monoclonal anti-vinculin/fpg-9, sheep anti- 
mouse IgG-FITC.  Immunocytochemical controls consisted of anti-u-PA- 
IgG preabsorbed with highly purified u-PA (29), preimmune IgG from the 
u-PA-immunized rabbit or mouse monoclonal anti-TNP-IgG,  as well as 
omission of any one of the steps in the staining procedure. After rinsing with 
PBS the coverslips were mounted in glycerol-PBS. The specimens were 
viewed with an EB microscope (Leitz Dialux, Wetzlar,  Germany) and pho- 
tographed as previously described (35). 
Immunoferritin Electron Microscopy 
To select an optimal method of processing the cells for experiments at the 
EM level, we tested several alternatives in immunofluorescence  using FITC- 
conjugated anti-ferritin-lgG (22). The cells were fixed with various concen- 
trations of  paraformaldehyde (0.1-4 %) and/or glutaraldehyde (0.01-2 %, EM 
grade; Leiras, Turku, Finland), either before or after the entire labeling se- 
quence, or after treatment with the primary antibody. 
In the immunoferritin experiments, cultured HT-1080 cells were briefly 
rinsed three times with Dulbecco's PBS (DPBS) containing 0.2% BSA at 
0~  and  then  incubated with the primary antibody (anti-u-PA-IgG,  50 
gg/ml). After gently rinsing three times with DPBS-BSA, labeling was per- 
formed using the ferritin bridge procedure (51) with incubations in the fol- 
lowing sequence: affinity purified goat anti-rabbit IgG (100 p.g/ml; Jackson 
Immuno Research Laboratories Inc., Avondale, PA), affinity-purified rabbit 
anti-horse ferritin (100 p.g/ml;  Jackson  Immuno  Research Laboratories 
Inc.), ferritin (100 gg/ml; Sigma Chemical Co., St. Louis, MO). Each step 
of the labeling sequence was performed at 0~  for 30 min and was followed 
by three 5-min rinses with DPBS-BSA. Then the cells were fixed with 2 % 
glutaraldehyde (Leiras) in 0.1 M phosphate buffer,  pH 7.2,  for 30 min. As 
a specificity control for the immunoferritin staining, 50 I~g/ml of the preim- 
mune IgG was used. The rinsed samples were postfixed with 1.5% OsO4 
in 0.1 M cacodylate buffer,  pH 7.2,  for 1 h at 23~  and dehydrated with 
ethanol. The culture dishes were mounted in Epon 812. After 2 d polymer- 
ization, the Epon blocks were sectioned vertically and horizontally against 
the cell layer. Thin sections were post-stained with uranyl acetate and lead 
citrate, and were observed and photographed in a Jeol 1200 EX electron mi- 
croscope at 60 kV at the Department of Electron Microscopy, University 
of Helsinki, Finland. The position of the u-PA antigen was estimated from 
photographic prints at a final magnifcation of 60,000.  From the prints, the 
distance of 200 ferritin cores was measured from perpendicularly sectioned 
segments of the plasma membrane. 
Results 
Distribution of  u-PA in lmmunoferritin 
Electron Microscopy 
To study the external distribution of u-PA at the EM level, 
we labeled HT-1080 sarcoma cells using the immunoferritin 
bridge procedure. In preliminary experiments, we tested sev- 
eral  methods  of processing  the  cells  for  immunofluores- 
cence  using  FITC-conjugated  anti-ferritin-IgG.  The  cells 
were fixed with paraformaldehyde and/or glutaraldehyde, ei- 
ther in the beginning or at the end of the entire ferritin bridge 
sequence, or after treatment with the primary antibody. Of 
these,  labeling of live cells at 0~  before fixation gave the 
strongest signal in the areas of cell-substratum contact, and 
detected exclusively extracellular antigen. The resulting pat- 
tern of u-PA staining was qualitatively  identical to that ob- 
tained using methanol prefixation in the ferritin bridge se- 
quence, as well as in conventional immunofluorescence (35; 
figures not shown). Thus, the pattern obtained by the anti- 
body treatment of live cells in the cold reflected the situa- 
tion at physiological temperature examined under prefixation 
conditions. 
At the EM level, the u-PA immunoreactivity was detected 
as  discrete  patches  of  ferritin  cores  associated  with  the 
plasma membrane. The ferritin was predominantly found at 
sites where the cells made contact with the growth substra- 
tum beneath all parts of the ventral cell surface.  Such con- 
tacts were best observed in sections cut vertically against the 
cell layer. These ferritin-labeled plaques had a close substra- 
tum separation distance of 15-50 nm (Fig.  1, A and B).  In 
rare instances, e.g., Fig.  1 A, some ferritin was on the growth 
substratum witht3ut any apparent relationship to the plasma 
membrane. The mean distance of the ferritin cores from the 
plasma membrane at these locations, such as illustrated in 
Fig.  1, was 21  +  5  nm. These plaques were enriched in a 
thick  submembraneous patch of microfilaments and  were 
frequently seen at the leading lamellae of the cell (Fig.  1, C, 
D,  and G). 
The Journal  of Cell Biology,  Volume  106, 1988  88 Figure L  Immunoferritin EM labeling for u-PA in cultures of HT-1080 cells using polyclonal rabbit IgG. The cells were stained live with 
the immunoferritin bridge procedure at :t:0~  before fixation with 2% glutaraldehyde. Note the plasma membrane-associated ferritin label- 
ing at focal celt adhesion sites (A-G).  A  and B are from the central regions of the cell; C, D, and G from the leading lamellae; E and 
F  from cross-sectioned cell extensions (lamellipodiae). Vertical thin sections with uranyl acetate-lead citrate post-staining. Bar, 100 nm. 
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lar extensions (lamellipodia and microspikes) and the sub- 
stratum (Fig.  1, E and F). Such microspikes could be well 
visualized in horizontal sections made along the cell-sub- 
stratum interface (Fig. 2). These extensions were also often 
enriched in a submembraneous patch of microfilaments, the 
linear orientation of which is clearly seen inside the micro- 
spikes in Fig.  2, A and B. 
In addition to the cell-substratum adhesion plaques, ferri- 
tin had a preferential localization at sites of cell-ceU contact 
(Fig. 3, A and B). Control cultures in which the primary anti- 
body was substituted with 50 lxg/ml preimmune u-PA IgG, 
gave virtually no binding of ferritin cores to the plasma mem- 
brane (Fig. 4). 
Characterization  of u-PA-conmining  Sites 
as Focal Contacts 
To further characterize the sites with u-PA immunoreactivity 
seen at the EM level, we performed double immunofluores- 
cent labeling of cultured HT-1080 and WI-38 cells with poly- 
clonal  anti-u-PA  IgG  and  monoclonal  anti-vinculin  IgG. 
Focalized u-PA immunoreactivity was found in all parts of 
the ventral cell surface, including the trailing edge, and in 
considerable  amounts  at  the  leading  edge.  Additionally, 
diffuse granular intracellular localization of u-PA was de- 
tected (Figs.  5 B  and 6 B). u-PA and vinculin displayed a 
striking colocalization at the focal contact sites on the ven- 
tral cell surface (Fig. 5, A and B). A similar codistribution 
of u-PA and vinculin was also detected in WI-38 human em- 
bryonic lung fibroblasts (Fig. 6, A and B). In these cells the 
labeled sites were a little more elongated than those in the 
HT-1080 cells. 
We also compared the distributions of u-PA and fibronec- 
tin in these two cell lines. HT-1080 cells deposit very little 
pericellular matrix fibronectin in contrast to WI-38 fibro- 
blasts grown for 24 h in 10%  serum.  As judged by double 
immunofluorescent labeling, most of the fibronectin fibrils 
were not superimposed with the u-PA and vinculin contain- 
ing contact sites in WI-38 cultures (Fig.  6,  C and D). 
In WI-38 lung fibroblasts growth arrested in 0.5%  FCS, 
anti-u-PA label diminished markedly. Specifically, no focal- 
ized u-PA immunostaining was seen after 4 d of serum deple- 
tion. Double-label immunofluorescence of the ceils at this 
stage detected vinculin arranged in highly elongated striae 
that were more centrally located (Fig. 7, A and B). The sta- 
tionary WI-38 cells deposited an abundant fibronectin ma- 
trix (not shown). Confluent control cultures grown in  10 % 
serum for 4 d showed a colocalization of u-PA and vinculin 
(not illustrated) similar to that in Fig. 6, A and B. 
Each  staining  reaction was  specific as  tested  by either 
u-PA-blocked or preimmune anti-u-PA IgG, as shown before 
(35), or using anti-TNP-IgG, and/or by omission of any step 
in the staining sequence (figures not shown). 
Discussion 
In the present study, we have shown that urokinase-type plas- 
minogen activator is an intrinsic component of focal contacts 
of human lung fibroblasts and sarcoma cells, in contrast to 
the two other types of cell-substratum contact, i.e.  close 
Figure 2.  Immunoferritin EM labeling 
for u-PA on HT-1080 cells:  staining of 
live cells at +0~  by the immunoferritin 
bridge  procedure  before  fixation with 
2 % glutaraldehyde. Thin sections were 
cut horizontally against the cell layer. 
Ferritin labeling is seen on the plasma 
membrane in lamellipodia and micro- 
spikes (A and B).  Uranyl acetate-lead 
citrate post-staining. Bar, 100 nm. 
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ing for u-PA (A and B) on HT-1080 
cells.  Staining of the cells at  +0~ 
before fixation with 2%  glutaralde- 
hyde. Note the ferritin patches asso- 
ciated with the plasma membrane at 
sites of  cell-cell contacts. Horizontal 
(A) and vertical (B) thin sections with 
uranyl acetate-lead citrate post-stain- 
ing. Bars, 100 nm inA, 200 nm in B. 
contacts and fibronexuses, in which u-PA was not detected. 
This fnding was based upon (a) immuno-EM, and (b) dou- 
ble-label immunofluorescence of u-PA and vinculin. In addi- 
tion to focal contacts, u-PA was located at cell-cell contact 
sites.  In  previous  cell  fractionation  studies,  PA  has  been 
generally detected in membrane-rich fractions (reviewed in 
reference 16). These biochemical studies did not, however, 
exclude the possibility that u-PA became bound to the mem- 
branes  after  disruption  of  cells.  The  immuno-EM  data 
presented  here  (Figs.  1-3)  show that  u-PA  was located at 
specific sites on the extracellular aspect of the plasma mem- 
brane.  This  is  consistent  with  recent  reports  on  specific 
cell-surface receptors for u-PA (reviewed in reference 3, 4). 
In immunoferritin bridge electron microscopy of sarcoma 
cells,  plasma membrane-associated u-PA  antigen  was de- 
tected at (a) adhesion plaques, (b) cell-cell contacts, and (c) 
on cellular extensions, lamellipodia and microspikes. These 
features in the ultrastructural localization of u-PA distinguish 
it, e.g. from the major extracellular matrix protein fibronec- 
tin, which is not located at close cell-cell contacts (22). The 
possibility  that  the  ferritin  patches  obtained  were due  to 
antibody-induced redistribution of the u-PA antigen  seems 
remote, because the labeling protocol used in immuno-EM 
gave an identical staining pattern with methanol prefixation 
followed by the same ferritin bridge sequence when tested at 
the immunofluorescence level.  The u-PA containing  adhe- 
sion plaques, which were generally found in all parts of the 
ventral  cell  surface,  were  frequently  seen  at  the  leading 
lamellae of the cells, bearing a close resemblance in ultra- 
structure to those described in motile fibroblasts (1). Earlier 
studies on normal locomotory fibroblasts have shown that 
new focal contacts are formed at the active edge by advancing 
P611~inen et al.  Urokinase at Focal Contacts  91 Figure 4.  Specificity  control for immunoferritin  labeling.  HT-1080 cultures were stained with 50 ltg/ml preimmune anti-u-PA IgG as the 
primary antibody. No ferritin particles  are seen in the vertical thin section that features a cellular extension in contact with the substratum. 
Bar,  100 nm. 
microspikes and lamellipodia, but later the contacts increased 
in size (5,  24).  On the other hand,  few reports exist on the 
focal contacts of transformed cells  (36). 
Double-label immunofluorescence showed a striking colo- 
calization of u-PA and vinculin in HT-1080 cells and WI-38 
fibroblasts.  The u-PA plaques  had no direct codistribution 
with fibronectin fibrils in WI-38 cells.  Both these features, 
the presence of vinculin (19, 20) and the apparent absence of 
fibronectin (9 and references quoted therein),  have been re- 
ported to be characteristic of focal contacts. However, u-PA 
was not found in adhesions made by stationary fibroblasts in 
0.5 % serum.  During such conditions u-PA immunostaining 
Figure 5. Double immunofluorescent  localization of vinculin (A) and u-PA (B) in HT-1080 fibrosarcoma cells prefixed with -20~  metha- 
nol. (A) Vinculin staining using monoclonal anti-vinculin mouse IgG. FITC fluorescence.  (B) The same cells stained with polyclonal anti- 
u-PA rabbit IgG. TRITC fluorescence.  The sequence  in the staining  procedure is described in Materials  and Methods.  Note the striking 
colocalization of vinculin and u-PA at discrete  sites on the ventral  cell  surface.  Bar,  15 I.tm. 
Figure 6.  Double immunofluorescent  localization  of vinculin (A) and u-PA (B); and fibronectin  (C) and u-PA (D) in WI-38 human em- 
bryonic lung fibroblasts  prefixed with methanol.  Primary antibodies:  monoclonal anti-vinculin mouse IgG (A), polyclonal anti-u-PA IgG 
(B and D), monoclonal fpg-9 antifibronectin  (C). Anti-u-PA labeling  codistributes  with vinculin plaques,  but is apparently unrelated  to 
the fibronectin  fibrils.  Bar,  15 ~tm. 
The Journal of Cell Biology, Volume 106, 1988  92 P611~tnen et al,  Urokinase at Focal Contacts  93 Figure 7. Double immunofluorescent labeling of vinculin (,4) and u-PA (B) in quiescent WI-38 fibroblasts cultured in 0.5% FCS for 4 d. 
Prefixation, labeling conditions identical to those in Figs. 5 and K Note simultaneous disappearance of u-PA immunostaining from the 
focal contact sites and the elongation of the vinculin plaques. Bar, 15 lxm. 
disappeared from the contact sites whereas vinculin plaques 
became highly elongated, and more centrally located. These 
results are in line with the earlier cell fractionation data (25, 
26), which showed u-PA in the plasma membrane-enriched 
fraction in growing and transformed 3T3 cells, whereas in 
quiescent cultures PA was almost exclusively intracellular 
and of the tissue type. The results also agree with a recent 
report showing that u-PA mRNA is increased in quiescent 
cultured fibroblasts and keratinocytes upon growth stimula- 
tion (21). The elongation of the vinculin plaques in quiescent 
WI-38  fibroblasts is consistent with earlier findings  (43), 
also describing the induction of fibronexus contact sites un- 
der similar conditions. The well-spread phenotype is thought 
to be maintained by tensile forces mediated by the actin- 
containing  microfilaments (20).  Moreover, the  contracted 
state of fibroblasts has been associated with decreased motil- 
ity and the beginning of growth (13, 14). 
The confinement of u-PA to focal contacts of fibroblasts 
under serum-containing conditions when the cells are motile 
would suggest a role for plasma membrane-associated u-PA 
in the attachment-detachment sequence. At this specific lo- 
calization, u-PA could then enable directional proteolysis for 
cell migration and invasion. It should be noted that the ex- 
periments reported here studied the distribution of  u-PA anti- 
gen, and not the expression of u-PA enzyme activity. Al- 
though many types of cells secrete mainly the pro-u-PA form 
(17, 32, 44, 45, 52), it remains unknown whether the u-PA 
at the focal contacts is actually in that proenzyme form, as 
our polyclonal antibodies are able to detect active enzyme 
and enzyme-inhibitor complexes as well (31). Several levels 
of regulatory mechanisms are likely to operate to insure that 
net enzyme activity at the focal contacts would only be ex- 
pressed when it is required (4, 16). These include the levels 
of proenzyme activation vs.  inactivation, the specific fast- 
acting PA inhibitors, and matrix modulation of inhibition. 
However, the present data establish that there is a  process 
resulting  in  selective accumulation  of the  enzyme to  the 
cell/matrix interface, and specifically to focal contacts. 
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